The therapeutic potential of high-intensity interval training in a breast cancer model: focus on the Hippo signaling pathway
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High-intensity interval training (HIIT) may mitigate breast cancer by modulating the Hippo signaling pathway. Exercise increased protective proteins and decreased oncogenic factors, reducing tumor volume in mice.
Area Of Science
- Oncology
- Molecular Biology
- Exercise Physiology
Background
- Contact inhibition, regulated by E-cadherin and the Hippo pathway, is crucial for cell proliferation.
- Dysregulation of these pathways is linked to breast cancer development.
- Physical exercise is known to reduce breast cancer risk, suggesting a potential role in modulating cancer pathways.
Purpose Of The Study
- To investigate the effect of high-intensity interval training (HIIT) on Hippo signaling in a mouse model of breast cancer.
- To explore the molecular mechanisms underlying exercise's influence on breast cancer progression.
Main Methods
- Four groups of mice (Control, Breast Cancer, Exercise, Breast Cancer + Exercise) were used.
- Western blot analysis assessed key proteins in the Hippo pathway (NF2, MST1/2, LATS1/2, TEAD, VGLL4, YAP, TAZ) and cell adhesion molecules (EGFR, E-cadherin, catenins).
- Tumor volume was measured in the breast cancer groups.
Main Results
- The Breast Cancer + Exercise group showed increased levels of protective proteins (EGFR, E-cadherin, α-catenin, β-catenin, Kibra, NF2, MST1/2, LATS1/2, P-YAP, VGLL4, P-TAZ) compared to the Breast Cancer group.
- Exercise groups exhibited lower levels of oncogenic proteins (YAP, TAZ, TEAD).
- Tumor volume was significantly reduced in the Breast Cancer + Exercise group.
Conclusions
- HIIT influences key components of the Hippo signaling pathway and cell adhesion molecules in breast cancer.
- These molecular changes correlate with reduced tumor growth.
- Exercise may offer a novel therapeutic strategy by targeting these pathways in breast cancer treatment.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...